Diosmin
drugOn this page
Also known as BarosminBuchu resinDaflonDiosminaDiosmineDiosvenDiovenDiovenorFlebavenFlebavenaFlebosmilFlebostenHemervenHesperidinInsuvenLitosmilNSC-758417ToveneVarinon
Summary
Diosmin (CHEMBL231884) is an approved small-molecule anti-inflammatory agent (ATC C05CA53); indicated across 8 conditions including cardiovascular disorder and venous insufficiency.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C05CA53 (+1 more)
- Indications: 8 conditions
- Clinical trials: 44
- Chemistry: 608.5 Da · C28H32O15
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL231884 |
| Name | Diosmin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5281613 |
| ChEBI | CHEBI:4631 |
| ATC | C05CA53, C05CA03 |
| Molecular formula | C28H32O15 |
| Molecular weight | 608.5 |
| InChIKey | GZSOSUNBTXMUFQ-YFAPSIMESA-N |
SMILES: C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
IUPAC name: 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
ChEBI definition: A disaccharide derivative that consists of diosmetin substituted by a 6-O-(α-L-rhamnopyranosyl)-β-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.
Pharmacological roles (ChEBI): antioxidant, anti-inflammatory agent.
Also known as: Barosmin, Buchu resin, Daflon, Diosmin, Diosmina, Diosmine, Diosven, Dioven, Diovenor, Flebaven, Flebavena, Flebosmil
Patent coverage: 1,929 distinct patent families (4,880 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 4,744 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Histone-lysine N-methyltransferase 2A, Inhibitor of nuclear factor kappa-B kinase subunit beta, Beta-lactamase, Menin/Histone-lysine N-methyltransferase MLL, Tumour suppressor protein p53/Mdm4, DNA polymerase beta, Lysine-specific histone demethylase 1A.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| IKBKB | 5.41 | IC50 | 3890 | nM | CHEMBL_ACT_22874937 |
| MDM4 | 5.41 | IC50 | 3890 | nM | CHEMBL_ACT_25872942 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| venous insufficiency | 3 | MONDO:0000945 | MONDO:0000945 |
| rheumatoid arthritis | 3 | MONDO:0008383 | EFO:0000685 |
| ulcerative colitis | 3 | MONDO:0005101 | EFO:0000729 |
| peptic ulcer disease | 3 | MONDO:0004247 | HP:0004398 |
| metabolic dysfunction-associated steatotic liver disease | 3 | MONDO:0013209 | EFO:0003095 |
| infertility disorder | 2 | MONDO:0005047 | EFO:0000545 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 44.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 17 |
| PHASE3 | 13 |
| PHASE4 | 5 |
| PHASE2 | 5 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07598214 | PHASE4 | RECRUITING | Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients |
| NCT03413618 | PHASE4 | COMPLETED | Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis |
| NCT03471910 | PHASE4 | COMPLETED | Clinical Non-inferiority Study Between Diosmin 600mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency |
| NCT04358497 | PHASE4 | UNKNOWN | Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome |
| NCT06083935 | PHASE4 | UNKNOWN | Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome |
| NCT05756179 | PHASE3 | RECRUITING | Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis |
| NCT06584799 | PHASE3 | RECRUITING | Venoactive Drug Treatment of Pelvic Venous Disorders |
| NCT06811220 | PHASE3 | NOT_YET_RECRUITING | The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients |
| NCT00330096 | PHASE3 | COMPLETED | Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women |
| NCT01110512 | PHASE3 | UNKNOWN | Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI) |
| NCT01321619 | PHASE3 | UNKNOWN | Efficacy and Tolerability of the Use of Varicell Compared With Daflon |
| NCT01477281 | PHASE3 | UNKNOWN | Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon |
| NCT01532882 | PHASE3 | COMPLETED | Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs |
| NCT02134249 | PHASE2/PHASE3 | COMPLETED | Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome |
| NCT02927483 | PHASE3 | UNKNOWN | Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency |
| NCT05243706 | PHASE3 | UNKNOWN | Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy |
| NCT05626166 | PHASE3 | UNKNOWN | the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis |
| NCT05670457 | PHASE3 | UNKNOWN | Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer |
| NCT05942547 | PHASE3 | UNKNOWN | the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis. |
| NCT06546111 | PHASE1/PHASE2 | RECRUITING | Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection |
| NCT00545116 | PHASE2 | COMPLETED | Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women |
| NCT00914251 | PHASE2 | UNKNOWN | Vascular Effects of Hesperidin in Metabolic Syndrome |
| NCT01773486 | PHASE2 | WITHDRAWN | Effects of Hesperidin on Insulin Sensitivity |
| NCT02610491 | PHASE2 | COMPLETED | The Effect of Hesperidin on Glucose / Insulin Metabolism |
| NCT02616731 | PHASE1/PHASE2 | UNKNOWN | Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD |
| NCT04715932 | PHASE2 | COMPLETED | Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) |
| NCT04452799 | EARLY_PHASE1 | UNKNOWN | Hesperidin and Diosmin for Treatment of COVID-19 |
| NCT06256575 | Not specified | RECRUITING | Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis |
| NCT06318988 | Not specified | NOT_YET_RECRUITING | Outcomes of Different Treatment Options in Chronic Venous Disease |
| NCT07293767 | Not specified | RECRUITING | Silymarin vs Hesperidin/Diosmin in Fibromyalgia |
| NCT07452562 | Not specified | RECRUITING | Hesperidin RCT in MS |
| NCT01881204 | Not specified | COMPLETED | Hesperidin and Bone Health in Postmenopausal Women |
| NCT03377140 | Not specified | UNKNOWN | The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease |
| NCT03377153 | Not specified | UNKNOWN | The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease |
| NCT03734835 | Not specified | UNKNOWN | The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Metabolic Syndrome |
| NCT03734874 | Not specified | UNKNOWN | The Effects of Hesperidin on Metabolic Syndrome |
| NCT03737422 | Not specified | COMPLETED | The Effects of Hesperidin and Flaxseed in Prediabetes |
| NCT03984916 | Not specified | COMPLETED | Study of the Bioavailability of Three Hesperidin Extracts. |
| NCT04316390 | Not specified | COMPLETED | Influence of Hesperidin and Vitamin C on Uric Acid Concentration |
| NCT04512443 | Not specified | COMPLETED | Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).